Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• A comprehensive investigation on liver regeneration: a meta-analysis and systems biology approach.1 passage
• A good response to steroid therapy in IgG4-related sclerosing cholangitis: a case report.1 passage
• A new model to predict response to direct-acting antiviral therapy in decompensated cirrhotics due to hepatitis C virus.1 passage
• A rare cause of gastrointestinal bleeding in the post-transplant setting.1 passage
• A systematic review and meta-analysis of evaluation of serum interleukin 8 levels in hepatocellular carcinoma.1 passage
• A systematic review of the present and future of non-alcoholic fatty liver disease.1 passage
• Accelerated hepatocellular carcinoma recurrence rate after postoperative direct-acting antivirals treatment - preliminary report.1 passage
• Acute hepatitis A virus infection in patients hospitalised at the Department of Infectious Diseases, Medical University of Lublin (Eastern Poland) in the years 2009-2015.1 passage
• Acute hepatitis A virus infection in patients hospitalized at the Department of Infectious Diseases, Medical University of Lublin (Eastern Poland) in 2017 - a hospital-based retrospective study.1 passage
• Acute-on-chronic hepatitis. A case report of autoimmune hepatitis/primary sclerosing cholangitis/ulcerative colitis overlap syndrome in a 15-year-old patient.1 passage
• Acute-on-chronic liver failure: a single-centre experience.1 passage
• Allopurinol potentiates the hepatoprotective effect of metformin and vitamin E in fructose-induced fatty liver in rats.1 passage
• An updated review of cystic hepatic lesions.1 passage
• Animal Naming Test - a simple and accurate test for diagnosis of minimal hepatic encephalopathy and prediction of overt hepatic encephalopathy.1 passage
• Antiviral therapy in hepatitis C-infected patients prevents relapse of diffuse large B cell lymphoma.1 passage
• Antiviral therapy of chronic HBV infection in pregnancy.1 passage
• Assessing the consistency of liver fibrosis results obtained through biopsy and transient elastography in patients suffering from chronic hepatitis C.1 passage
• Assessment of hepatitis B virus pregenomic RNA in high and low viremic chronic hepatitis B patients.1 passage
• Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in colorectal liver metastases: review of the literature.1 passage
• Association between interleukin 6 polymorphisms (rs1800796, rs1800795, rs2069837, rs17147230, and rs1800797) and hepatocellular carcinoma susceptibility: a meta-analysis.1 passage
• Association of TNF-α and CCL5 with response to interferon-based therapy in patients with HCV 1 genotype.1 passage
• Autoimmune hepatitis and pregnancy: report of two cases with different maternal outcomes.1 passage
• Autoimmune reactions in the course of the hepatitis C virus (HCV) infection.1 passage
• Brain-derived neurotrophic factor as a potential diagnostic marker in minimal hepatic encephalopathy.1 passage
• CD62P (P-selectin) expression as a platelet activation marker in patients with liver cirrhosis with and without cholestasis.1 passage
• Can adequate analgesia be achieved in patients with cirrhosis without precipitating hepatic encephalopathy? A prospective study.1 passage
• Cannulation in patients with large periampullary diverticulum using SpyBite miniforceps.1 passage
• Cellulitis in liver cirrhosis - a series of 25 cases from southern India.1 passage
• Change in γ-glutamyl transpeptidase activity as a useful tool in identifying a group of patients with elevated risk of hepatocellular carcinoma development after DAA treatment of chronic hepatitis C.1 passage
• Chronic hepatitis B virus infection is associated with decreased serum 25(OH)D concentration in non-cirrhotic patients.1 passage
• Clinical aspects and treatment of hepatocellular carcinoma in north-eastern Poland.1 passage
• Clinical audit to determine efficacy of daily infusion of low dose of 20% albumin in combination with antibiotics in patients with spontaneous bacterial peritonitis.1 passage
• Clinical effectiveness of MARS treatment - multidirectional analysis of positive clinical response to treatment.1 passage
• Clinical effects of simvastatin in chronic hepatitis C patients receiving sofosbuvir/daclatasvir combination. A randomized, placebo-controlled, double-blinded study.1 passage
• Clinical usefulness of new noninvasive serum biomarkers for the assessment of liver fibrosis and steatosis in children with chronic hepatitis C.1 passage
• Clinical, serological, histopathological and treatment profile of autoimmune hepatitis in the elderly.1 passage
• Comparative analysis of metabolic risk factors for progression of non-alcoholic fatty liver disease.1 passage
• Comparative study of the effects of Abexol and atorvastatin in patients with non-alcoholic fatty liver disease.1 passage
• Comparison of hepatic and splenic stiffness in chronic hepatitis C infection with and without schistosomal infection; correlation with hepatic histopathological changes.1 passage
• Comparison of knowledge and awareness between consultant physicians and resident doctors about non-alcoholic fatty liver disease.1 passage
• Comparison of pre-S1/S2 variations of hepatitis B virus between asymptomatic carriers and cirrhotic/hepatocellular carcinoma-affected individuals.1 passage
• Congenital hepatic fibrosis in a 9-year-old female patient - a case report.1 passage
• Correlation of endoscopic findings with Doppler ultrasound in portal hypertension in children.1 passage
• Diagnosis of spontaneous bacterial peritonitis in children using leukocyte esterase reagent strips and granulocyte elastase immunoassay.1 passage
• Diagnostic yield of magnetic resonance imaging for cholangiocarcinoma in primary sclerosing cholangitis: a meta-analysis.1 passage
• Direct antiviral agents for chronic hepatitis C virus infection improve health-related quality of life significantly in the long term.1 passage
• Distribution of HBV genotypes in Poland.1 passage
• Effect of abdominal fat distribution on severity of acute pancreatitis.1 passage
• Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C - a real-world study.1 passage
• Effect of hepatitis B virus (HBV) infection on the course of pregnancy and newborns' health status.1 passage
• Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients.1 passage
• Effects of infection on post-transplant outcomes: living versus deceased donor liver transplants.1 passage
• Efficacy and direct costs of chronic hepatitis C treatment with first generation NS3/4A protease inhibitors in a real life population.1 passage
• Efficacy and safety of N-acetylcysteine for the treatment of non-acetaminophen-induced acute liver failure: an updated systematic review and meta-analysis.1 passage
• Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study.1 passage
• Elevated circulating endothelial cell-derived microparticle levels in patients with liver cirrhosis: a preliminary report.1 passage
• Elevated cystatin C: is it a reflection for kidney or liver impairment in hepatic children?1 passage
• Epidemiological investigation on hepatitis A virus infection outbreak in the area of Rzeszow city during the years 2017/18.1 passage
• Epidemiology of gallbladder cancer.1 passage
• Epidemiology of non-alcoholic fatty liver disease and risk of hepatocellular carcinoma progression.1 passage
• Estimation of the risk of fibrosis in children with nonalcoholic fatty liver disease.1 passage
• Evaluation of different diagnostic modalities of minimal hepatic encephalopathy in cirrhotic patients: case-control study.1 passage
• Evaluation of hepatic fibrosis - access to non-invasive methods, national practice/guidelines in Central Europe.1 passage
• Evaluation of serum interleukin-10 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis.1 passage
• Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis.1 passage
• Expression of intrahepatic CD3, CD4, and CD8 T cells in biliary atresia.1 passage
• Expression of vascular endothelial growth factor A in liver tissues of infants with biliary atresia.1 passage
• Extra-abdominal involvement is associated with antitubercular therapy-related hepatitis in patients treated for abdominal tuberculosis.1 passage
• FIB-4 and APRI scores for predicting severe liver fibrosis in chronic hepatitis HCV patients: a monocentric retrospective study.1 passage
• FIB-5 versus FIB-4 index for assessment of hepatic fibrosis in chronic hepatitis B affected patients.1 passage
• Factors predicting recovery of liver function after percutaneous drainage in malignant biliary obstruction: the role of hospital-acquired biliary sepsis.1 passage
• Fas, FasL and Foxp3 gene expression in post-liver transplant autoimmune hepatitis patients with and without acute rejection.1 passage
• Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development.1 passage
• Glutathione S-transferase T1 and M1 null genotype distribution among non-alcoholic fatty liver disease patients and its association with cytokine and adipokine profiles.1 passage
• Glutathione peroxidase and malondialdehyde in children with chronic hepatitis C.1 passage
• Health-related quality of life in liver cirrhosis patients using SF-36 and CLDQ questionnaires.1 passage
• Hemospray for recurrent esophageal band ulcer bleeding.1 passage
• Hepatic ballooning degeneration: a new feature of the refeeding syndrome in rats.1 passage
• Hepatic expression of programmed death-1 (PD-1) and its ligand, PD-L1, in children with autoimmune hepatitis: relation to treatment response.1 passage
• Hepatic infarction and acute pancreatitis: a case report and review of the literature.1 passage
• Hepatic interferon γ and tumor necrosis factor a expression in infants with neonatal cholestasis and cytomegalovirus infection.1 passage
• Hepatitis B virus treatment in hepatocellular carcinoma patients prolongs survival and reduces the risk of cancer recurrence.1 passage
• Hepatitis C is now curable, but what happens with cirrhosis and portal hypertension afterwards?1 passage
• Hepatitis C virus antibodies in outpatients with chronic kidney disease.1 passage
• Hepatitis D, B and C virus (HDV/HBV/HCV) coinfection as a diagnostic problem and therapeutic challenge.1 passage
• Hepatocellular carcinoma - an unusual metastatic presentation on the chest wall.1 passage
• Hepatocellular carcinoma after direct-acting antivirals: an unresolved problem. Review of five cases.1 passage
• Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis - epidemiology, risk factors, clinical implications and treatment.1 passage
• Hepatocellular carcinoma recurrence after directly acting antivirals for chronic hepatitis C: a 2-year follow-up study.1 passage
• Hepatology topics of special interest from Central Europe (Czech Republic, Hungary, Poland, Slovakia).1 passage
• How close are we to hepatitis C virus elimination in Central Europe?1 passage
• How frequent is sleep-disordered breathing among Egyptian cirrhotic adults?1 passage
• Hyaluronic acid as a potential marker for assessment of fibrosis regression after direct acting antiviral drugs in chronic hepatitis C patients.1 passage
• IgG4 subclass and gamma-glutamyl transferase in children with ulcerative colitis with primary sclerosing cholangitis and without sclerosing cholangitis.1 passage
• Immune regulation and viral diversity as correlates of natural and treatment induced immune control in persistent hepatitis B virus (HBV) infection.1 passage
• Immunodeficiency caused by cirrhosis.1 passage
• Impact of liver-directed therapy and non-therapy on the waiting time list of patient candidates for liver transplantation: retrospective survival analysis.1 passage
• Impact of rs12979860 polymorphism on liver morphology in chronic HCV infection.1 passage
• Increased serum glypican-3 is associated with liver stiffness and hepatic dysfunction in children with biliary atresia.1 passage
• Influence of ursodeoxycholic acid therapy on levels of fibroblast growth factor 21, adiponectin and biochemical parameters in intrahepatic cholestasis of pregnancy.1 passage
• Insulin resistance and its consequences in chronic hepatitis C.1 passage
• Interventional radiological management of hepatobiliary disorders in pregnancy.1 passage
• Intrahepatic splenosis: a world review.1 passage
• Left ventricular diastolic dysfunction in liver transplantation: a stronger association with non-alcoholic steatohepatitis.1 passage
• Liver function test abnormalities in COVID-19 patients and factors affecting them - a retrospective study.1 passage
• Liver pathology in children with newly diagnosed celiac disease.1 passage
• Lymphovascular invasion on explant is associated with presenting tumor characteristics and not direct acting antiviral utilization in hepatitis C candidates undergoing liver transplantation.1 passage
• Mac-2 binding protein in non-alcoholic fatty liver disease: Is it a reliable diagnostic biomarker? A pilot study.1 passage
• Megamitochondria formation in hepatocytes of patient with chronic hepatitis C - a case report.1 passage
• Metabolic associated fatty liver disease and adverse maternal and fetal outcomes: a systematic review and meta-analysis.1 passage
• MicroRNA-499 rs3746444 polymorphism in Egyptian children with biliary atresia.1 passage
• Missed opportunities for diagnosing viral hepatitis C in Poland. Results from routine HCV testing at the Emergency Department in the Hospital for Infectious Diseases in Warsaw.1 passage
• N-acetyl cysteine treatment preserves mitochondrial indices of functionality in the brain of hyperammonemic mice.1 passage
• New directions in hepatitis B therapy research.1 passage
• New therapeutic options for HCV in Central Europe.1 passage
• Non-alcoholic fatty liver disease and lipotoxicity.1 passage
• Non-invasive assessment of liver fibrosis in alcoholic liver disease.1 passage
• Non-invasive evaluation of the liver disease severity in children with chronic viral hepatitis using FibroTest and ActiTest - comparison with histopathological assessment.1 passage
• Normalizing serum hepcidin but not α-1-antitrypsin level during effective treatment of chronic hepatitis C.1 passage
• Nutrition principles and recommendations in different types of hepatic encephalopathy.1 passage
• Nutritional status in patients with liver cirrhosis.1 passage
• Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy.1 passage
• Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus.1 passage
• Outpatient versus inpatient follow-up for intrahepatic cholestasis of pregnancy.1 passage
• Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma.1 passage
• Paracentesis-induced acute kidney injury in decompensated cirrhosis - prevalence and predictors.1 passage
• Pediatric chronic liver failure-sequential organ failure assessment score and outcome of acute liver failure in children.1 passage
• Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease.1 passage
• Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study.1 passage
• Perspectives of hepatitis C virus (HCV) elimination in Poland.1 passage
• Physician awareness of hepatitis C virus among different departments.1 passage
• Portal cavernoma in a case of alcoholic liver disease with myeloproliferative neoplasm.1 passage
• Predictive power of Model for End-Stage Liver Disease and Child-Turcotte-Pugh score for mortality in cirrhotic patients.1 passage
• Predictive utility of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in intraductal papillary neoplasm of the bile duct.1 passage
• Predictors for hepatocellular carcinoma recurrence after microwave ablation.1 passage
• Predictors of azathioprine toxicity in children with autoimmune hepatitis.1 passage
• Predictors of sustained virological response in patients with hepatitis C virus genotype 3 infection.1 passage
• Preoperative alkaline phosphatase is a potential predictor of short-term outcome of surgery in infants with biliary atresia.1 passage
• Prevalence and clinical profile of glycogen storage diseases in children from Western India.1 passage
• Prevalence and predictors of post-liver transplantation metabolic bone diseases.1 passage
• Prevalence and prognostic value of cirrhotic cardiomyopathy as defined according to the proposed new classification.1 passage
• Prevalence and risk factors of non-alcoholic fatty liver disease in southwest Iran: a population-based case-control study.1 passage
• Prevalence of HCV genotypes in Poland - the EpiTer study.1 passage
• Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls - PRO-CARDIO-C study.1 passage
• Prevalence of hepatitis delta infections among HBs-antigen-positive inhabitants of southeastern and northwestern parts of Poland.1 passage
• Profile of extrahepatic portal venous obstruction among children in Central India.1 passage
• Profiling of plasma metabolomics in patients with hepatitis C-related liver cirrhosis and hepatocellular carcinoma.1 passage
• Prophylaxis of hepatitis B virus (HBV) infection reactivation - recommendations of the Working Group for prevention of HBV reactivation.1 passage
• Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection.1 passage
• Recommendations for the management of non-alcoholic fatty liver disease (NAFLD).1 passage
• Recommendations for the treatment of hepatitis B in 2017.1 passage
• Recommendations for the treatment of hepatitis C in 2017.1 passage
• Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020.1 passage
• Relation between levels of toll-like receptors 3 and 7 and clinical profile of Child-Pugh B cirrhotic patients.1 passage
• Retreatment of symptomatic hepatitis C virus genotype 3 associated mixed cryoglobulinemia with sofosbuvir and ribavirin: a case report.1 passage
• Risk factors predicting nosocomial, healthcare-associated and community-acquired infection in spontaneous bacterial peritonitis and survival outcome.1 passage
• Role of interleukin 6 in liver cell regeneration after hemi-hepatectomy, correlation with liver enzymes and flow cytometric study.1 passage
• Role of quantitative hepatitis B surface antigen levels in predicting liver biopsy time in treatment-naive chronic hepatitis B patients.1 passage
• SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review.1 passage
• SX-Ella Danis stent in massive upper gastrointestinal bleeding in cirrhosis - a case series.1 passage
• Searching for the optimal population for hepatitis C virus screening in Poland.1 passage
• Serum and ascitic D-dimer in cirrhotic patients with spontaneous bacterial peritonitis.1 passage
• Serum concentrations of selected adipokines in virus-related liver cirrhosis and hepatocellular carcinoma.1 passage
• Serum level of interleukin-13 receptor alpha 2 in infants with biliary atresia - is it of value?1 passage
• Severe fatty liver disease and acute pancreatitis: is there a correlation between them?1 passage
• Severe intrahepatic cholestasis and liver failure after stanozolol usage - case report and review of the literature.1 passage
• Should patients with unresectable gallbladder cancer with hilar involvement undergo unilateral or bilateral percutaneous biliary drainage in the setting of cholangitis?1 passage
• Simple non-invasive markers for early diagnosis and determination of the severity of liver diseases.1 passage
• Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease.1 passage
• Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients - short report.1 passage
• Soluble CD25 as a predictor of hepatocellular carcinoma compared with alpha-fetoprotein.1 passage
• Spontaneous bacterial peritonitis - therapeutic challenges in the era of increasing drug resistance of bacteria.1 passage
• Study of Dickkopf-1 (DKK-1) in patients with chronic viral hepatitis C-related liver cirrhosis with and without hepatocellular carcinoma.1 passage
• Study of predictive factors of complete response after chemoembolization for unresectable hepatocellular carcinoma in 162 patients.1 passage
• Successful outcome of therapy of acute hepatitis C following sexual and parenteral exposure - report of two cases.1 passage
• Surgical treatment of liver tumors - own experience and literature review.1 passage
• Surveillance for portal hypertension in the course of liver cirrhosis.1 passage
• Taurine mitigates bile duct obstruction-associated cholemic nephropathy: effect on oxidative stress and mitochondrial parameters.1 passage
• The association between juvenile autoimmune hepatitis and HLA-DRB1 alleles: Iraqi tertiary center experience.1 passage
• The association between obstructive sleep apnea and non-alcoholic steatohepatitis: a retrospective nationwide inpatient sample analysis.1 passage
• The clinical significance of serum miRNA-224 expression in hepatocellular carcinoma.1 passage
• The effect of silymarin on liver enzymes and antioxidant status in trauma patients in the intensive care unit: a randomized double blinded placebo-controlled clinical trial.1 passage
• The effect of water intake on ultrasound tissue characteristics and hemodynamics of adult livers.1 passage
• The epidemiology of hepatocellular cancer in Poland.1 passage
• The impact of the recipient and donor interferon lambda-3 polymorphism on the course of HCV infection following liver transplantation.1 passage
• The importance of nutrition for pediatric liver transplant patients.1 passage
• The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases.1 passage
• The influence of anti-HBc status on the sustained virological response rate in HCV-infected patients treated with pegylated interferon alfa 2 and ribavirin.1 passage
• The interplay between Th17 and T-regulatory responses as well as adipokines in the progression of non-alcoholic fatty liver disease.1 passage
• The occurrence of autoantibodies in patients with chronic HCV infection, including patients dialyzed and after kidney transplantation.1 passage
• The prevalence and severity of 25-(OH)-vitamin D insufficiency in HCV infected and in HBV infected patients: a prospective study.1 passage
• The risk of complications of endoscopic procedures in patients with liver cirrhosis.1 passage
• The role of metabolic disorders in the pathogenesis of intrahepatic cholestasis of pregnancy.1 passage
• The usefulness of commercially available serological tests in the diagnosis and monitoring of treatment in patients with alveolar echinococcosis.1 passage
• Toxic hepatitis caused by the excretions of the1 passage
• Transient elastography reliably estimates liver fibrosis in autoimmune hepatitis.1 passage
• Treg cells in the course of chronic hepatitis C virus infection partially normalize in longitudinal observation after successful DAA treatment regardless of hepatic fibrosis stage.1 passage
• Underrated enemy - from nonalcoholic fatty liver disease to cancers of the gastrointestinal tract.1 passage
• Unusual acute liver failure from small cell carcinoma of the lung.1 passage
• Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children.1 passage
• Variant etiologies of neonatal cholestasis and their outcome: a Middle East single-center experience.1 passage
• Viral hepatitis C treatment shortening - what is the limit?1 passage
• Visfatin serum concentration and hepatic mRNA expression in chronic hepatitis C.1 passage
• Vitamin D deficiency in patients with chronic hepatitis D viral infection.1 passage
• Whole exome sequencing analysis for mutations in isolated type III biliary atresia patients.1 passage